Latest

SpaceX: Is The Starlink TAM Overstated? A Critical Valuation Review (Archive)

SpaceX faces significant valuation risks despite its growth potential and Starlink market share.

19 Jun'26 Portfolio

Leaning into financials

Marvell: Set To Win From Hyperscalers' Custom Chip Programs (Archive)

Marvell is primed for explosive custom AI chip growth, despite premium valuation risks.

Astronics: On The Cusp Of A Production And Upgradation Upcycle (Archive, Full Access)

Astronics rides a powerful aircraft production, retrofit, and premium cabin systems upcycle tailwind.

Nova: Riding A Trillion‑Dollar Fab Capex Wave

Niche Metrology Leader With Outsized Upside In The WFE Supercycle

12 Jun'26 Portfolio

A very diversified global portfolio that is underweight technology

Novo Nordisk: Wegovy Pill Is Encouraging But Still Not Enough To Make Me Buy (Archive)

Wegovy pill expands US obesity share, but cash flow limits and GLP‑1 competition constrain upside.